argenx SE
ARGX-213
FcRn-targeted antibody
Countdown
177days
Phase 1 readout · ~ Dec 31, 2026 estimated
What's at stake
Phase 1 trial results for ARGX-213 in FcRn-targeted antibody are due ~ Dec 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 6-K
verified 12h ago
“ARGX-213 is expected to enter patient studies in 2026”